Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 4,001–4,025 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors.
· Cancer Res · 2022 · PMID 35027467 · validated civic_curation pubmed
A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer.
· Cancer Res · 2017 · PMID 28512242 · validated civic_curation pubmed
Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors.
· Cell Cycle · 2014 · PMID 24626198 · validated civic_curation pubmed
High-throughput Phenotyping of Lung Cancer Somatic Mutations.
· Cancer Cell · 2016 · PMID 27478040 · validated civic_curation pubmed
Tyrosine receptor kinase B is a drug target in astrocytomas.
· Neuro Oncol · 2017 · PMID 27402815 · validated civic_curation pubmed
Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene.
· Oncogene · 1997 · PMID 9191060 · validated civic_curation pubmed
Differentiation of NUT midline carcinoma by epigenomic reprogramming.
· Cancer Res · 2011 · PMID 21447744 · validated civic_curation pubmed
Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

Showing 4,001–4,025 of 4,399 publications

← Previous
1
…
160
161
162
…
176
Next →

· Nat Commun · 2019 · PMID 31784538 · validated civic_curation pubmed

Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.

· Cancer Res · 2020 · PMID 32973082 · validated civic_curation pubmed

Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR.

· Nat Commun · 2025 · PMID 40169546 · validated civic_curation pubmed

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer.

· NPJ Precis Oncol · 2021 · PMID 34272467 · validated civic_curation pubmed

Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.

· PLoS One · 2007 · PMID 17726540 · validated civic_curation pubmed

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

· Cancer Cell · 2007 · PMID 18068628 · validated civic_curation pubmed

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.

· Mol Cancer · 2014 · PMID 24735930 · validated civic_curation pubmed

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

· Mol Cancer Ther · 2015 · PMID 25398829 · validated civic_curation pubmed

Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.

· Tumour Biol · 2016 · PMID 26596839 · validated civic_curation pubmed

Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.

· Int J Cancer · 2016 · PMID 26686064 · validated civic_curation pubmed

Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38.

· Autophagy · 2015 · PMID 26391455 · validated civic_curation pubmed

Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.

· Mol Cancer Ther · 2015 · PMID 25939761 · validated civic_curation pubmed

Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.

· Anticancer Res · 2015 · PMID 26637881 · validated civic_curation pubmed

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.

· Oncotarget · 2015 · PMID 25883215 · validated civic_curation pubmed

Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.

· Oncogene · 2016 · PMID 25982282 · validated civic_curation pubmed

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

· Oncotarget · 2014 · PMID 25153719 · validated civic_curation pubmed

Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.

· Anticancer Drugs · 2014 · PMID 25089570 · validated civic_curation pubmed

Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.

· PLoS One · 2014 · PMID 24927325 · validated civic_curation pubmed